BIOMAT Database Logo BIOMAT Database Logo

Zotepine in the treatment of negative symptoms in chronic schizophrenia. 1987

W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber

Zotepine is a new tricyclic neuroleptic with a pharmacological profile comparable to substances like Thioridazine and Chlorpromazine. In an open pilot study, 10 patients suffering from negative symptoms in the course of chronic schizophrenia were treated with Zotepine. The efficacy of Zotepine in this indication was evaluated by means of the BPRS and the Andreasen Scale for the Assessment of Negative Symptoms. Significant improvement could be demonstrated after 3 weeks of treatment. No side effects were observed within the dosage range of 50 to 200 mg per die. These results suggest that Zotepine is useful in the treatment of residual schizophrenia.

UI MeSH Term Description Entries
D008297 Male Males
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003988 Dibenzothiepins
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D012565 Schizophrenic Psychology Study of mental processes and behavior of schizophrenics. Psychology, Schizophrenic
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Algorithm for the treatment of negative symptoms in chronic schizophrenia.
October 1999, Psychiatry and clinical neurosciences,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
The efficacy of zotepine in treating acute negative symptoms of schizophrenia: The results of a meta-analysis.
January 2000, International journal of psychiatry in clinical practice,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Negative symptoms and hypofrontality in chronic schizophrenia.
December 1992, Archives of general psychiatry,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
The differential diagnosis of negative symptoms in chronic schizophrenia.
December 1989, The Australian and New Zealand journal of psychiatry,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia.
January 2013, Indian journal of pharmacology,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Pharmacological treatment of negative symptoms in schizophrenia.
October 2015, European archives of psychiatry and clinical neuroscience,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Psychosocial treatment of negative symptoms in schizophrenia.
January 1990, Modern problems of pharmacopsychiatry,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Zotepine for schizophrenia.
January 2000, The Cochrane database of systematic reviews,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Zotepine for schizophrenia.
October 2006, The Cochrane database of systematic reviews,
W W Fleischhacker, and C Barnas, and C Stuppäck, and B Unterweger, and H Hinterhuber
Safety evaluation of zotepine for the treatment of schizophrenia.
July 2010, Expert opinion on drug safety,
Copied contents to your clipboard!